Possible Explanation for NKTR fall on Monday

NKTR fell 17% on 10/22, and it was difficult to find any news as to why.

It appears that Roche’s IL-2 variant has released positive Phase 1 results.

https://www.biocentury.com/bc-extra/clinical-news/2018-10-22…

On one hand, this creates potential competition for NKTR, but on the other hand, it reinforces the short report that helped drive the price down was based on faulty data. NKTR continues to fall harder than the other stocks in my universe, down over 5% today after being down 4% yesterday.

3 Likes

I read that NKTR has 10 abstracts at ASCO early November,so we shall soon know whether longer dated results are better.

https://ir.nektar.com/news-releases/news-release-details/nek…

Rob

1 Like

Yes, they have 10 abstracts approved, and one of those is regarding the PIVOT-02 trial. The person who put out the short report said there would be no update on this. The short report that had so much effect on the share price has been thoroughly debunked.

It’s actually SITC they will be presenting at. After market close on 11/9.

2 Likes

I read that NKTR has 10 abstracts at ASCO early November,so we shall soon know whether longer dated results are better.

Yes, 10 abstracts and on Nov 1st we will find out if they submitted any late breaking abstract that got approved.

Chris

2 Likes